SCHEDULE 13G: Anson Funds Group Discloses 9.9% Passive Stake in Hepion Pharmaceuticals

Anson Funds Management LP and its affiliates have reported a 9.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., primarily for investment purposes.

Summary

• Anson Funds Management LP, along with Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam, collectively reported beneficial ownership of 595,719 shares of Hepion Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.9% of the outstanding Common Stock of Hepion Pharmaceuticals, Inc.
• The percentage is calculated based on 5,473,126 shares issued and outstanding as reported on January 13, 2025, plus 490,034 shares receivable upon exercise of warrants, totaling 5,963,160 shares.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The beneficial ownership includes shares underlying outstanding warrants, which are subject to a limitation preventing ownership from exceeding 9.99% of the outstanding Common Stock upon exercise.

Sentiment

Score: 6

Explanation: The filing of a Schedule 13G indicates a significant passive investment by a reputable fund, which can be viewed positively as a vote of confidence. However, it provides no operational or financial updates on the company itself, so the sentiment is neutral to slightly positive based solely on the investor's interest.

Positives

• A significant institutional investor group, Anson Funds, has taken a substantial passive stake, which can be interpreted as a vote of confidence in Hepion Pharmaceuticals' long-term prospects.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, long-term investment approach rather than an activist one.

Risks

• The beneficial ownership includes shares underlying warrants, which, if fully exercised, could lead to dilution for existing shareholders, although the document notes a 9.99% beneficial ownership limitation on warrant exercise.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a multi-strategy investment firm in a biotechnology company, which is common for firms seeking exposure to the pharmaceutical sector's growth potential. The 9.9% stake is just below the 10% threshold that would typically trigger a more detailed Schedule 13D filing, suggesting a non-activist, passive investment strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by Anson Funds may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large passive investor may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Hepion Pharmaceuticals, Anson Funds, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Passive Stake, Biotechnology, Pharmaceuticals